Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis

Kim, S; Lee, BH; Zhang, X; Park, JW; Lee, S; Lee, H

Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis

Kim, S Lee, BH Zhang, X Park, JW Lee, S Lee, H

Permalink

Publication Type:: Journal Article
Citation:: European Journal of Integrative Medicine, 2017, 12 pp. 12 - 22
Issue Date:: 2017-06-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted ManuscriptAdobe PDF (1.51 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Kim, S	en_US
dc.contributor.author	Lee, BH	en_US
dc.contributor.author	Zhang, X	en_US
dc.contributor.author	Park, JW	en_US
dc.contributor.author	Lee, S	en_US
dc.contributor.author	Lee, H https://orcid.org/0000-0002-1107-9389	en_US
dc.date.issued	2017-06-01	en_US
dc.identifier.citation	European Journal of Integrative Medicine, 2017, 12 pp. 12 - 22	en_US
dc.identifier.issn	1876-3820	en_US
dc.identifier.uri	http://hdl.handle.net/10453/115974
dc.description.abstract	© 2017 Elsevier GmbH Introduction We conducted a systematic review and meta-analysis to evaluate the evidence for herbal medicine for inducing or maintaining remission in patients with ulcerative colitis (UC) and Crohn's disease (CD). Methods Eight databases were searched up to January 2017 for randomised controlled trials of herbal medicine as an adjunct to conventional medication in patients with inflammatory bowel disease (IBD). Data were extracted to obtain risk ratio (RR) of failure of inducing or maintaining remission, with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane criteria. Results Twenty-nine RCTs (24 UC, 5 CD) were included. In UC, herbal medicine was superior to placebo for clinical remission (RR of remission failure = 0.74, 95% CI: 0.59–0.93; I2 = 62%) and maintaining remission (RR of failure to maintain remission = 0.34, 95% CI: 0.17–0.67; I2 = 0%). Traditional Chinese patent medicine with standard therapy reduced the risk of no comprehensive remission by 19% compared to standard therapy alone (RR of no remission = 0.81, 95% CI: 0.70–0.95; I2 = 0%). In CD, however, the effect of herbal medicine was significant neither for inducing nor maintaining remission (RR of remission failure = 0.57, 95% CI: 0.24–1.33; I2 = 87%; RR of failure to maintain remission = 0.95, 95% CI: 0.60–1.52). Few serious adverse events were reported. Conclusions An adjunctive herbal medicine compared to standard therapy appears effective with few adverse events in achieving and maintaining remission in UC, while there is a lack of supporting evidence for CD. Future high quality trials are warranted.	en_US
dc.relation.ispartof	European Journal of Integrative Medicine	en_US
dc.relation.isbasedon	10.1016/j.eujim.2017.03.009	en_US
dc.title	Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis	en_US
dc.type	Journal Article
utslib.citation.volume	12	en_US
utslib.for	1104 Complementary and Alternative Medicine	en_US
utslib.for	11 Medical and Health Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access
pubs.publication-status	Published	en_US
pubs.volume	12	en_US

Abstract:

© 2017 Elsevier GmbH Introduction We conducted a systematic review and meta-analysis to evaluate the evidence for herbal medicine for inducing or maintaining remission in patients with ulcerative colitis (UC) and Crohn's disease (CD). Methods Eight databases were searched up to January 2017 for randomised controlled trials of herbal medicine as an adjunct to conventional medication in patients with inflammatory bowel disease (IBD). Data were extracted to obtain risk ratio (RR) of failure of inducing or maintaining remission, with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane criteria. Results Twenty-nine RCTs (24 UC, 5 CD) were included. In UC, herbal medicine was superior to placebo for clinical remission (RR of remission failure = 0.74, 95% CI: 0.59–0.93; I2 = 62%) and maintaining remission (RR of failure to maintain remission = 0.34, 95% CI: 0.17–0.67; I2 = 0%). Traditional Chinese patent medicine with standard therapy reduced the risk of no comprehensive remission by 19% compared to standard therapy alone (RR of no remission = 0.81, 95% CI: 0.70–0.95; I2 = 0%). In CD, however, the effect of herbal medicine was significant neither for inducing nor maintaining remission (RR of remission failure = 0.57, 95% CI: 0.24–1.33; I2 = 87%; RR of failure to maintain remission = 0.95, 95% CI: 0.60–1.52). Few serious adverse events were reported. Conclusions An adjunctive herbal medicine compared to standard therapy appears effective with few adverse events in achieving and maintaining remission in UC, while there is a lack of supporting evidence for CD. Future high quality trials are warranted.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/115974